Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Hepatitis: HELP
Articles by Clemens Hinterleitner
Based on 1 article published since 2009
(Why 1 article?)

Between 2009 and 2019, Clemens Hinterleitner wrote the following article about Hepatitis.
+ Citations + Abstracts
1 Article Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation. 2018

Grottenthaler, Julia M / Werner, Christoph R / Steurer, Martina / Spengler, Ulrich / Berg, Thomas / Engelmann, Cornelius / Wedemeyer, Heiner / von Hahn, Thomas / Stremmel, Wolfgang / Pathil, Anita / Seybold, Ulrich / Schott, Eckart / Blessin, Usha / Sarrazin, Christoph / Welker, Martin-Walter / Harrer, Ellen / Scholten, Stefan / Hinterleitner, Clemens / Lauer, Ulrich M / Malek, Nisar P / Berg, Christoph P. ·Department of Gastroenterology, Hepatology, and Infectiology, University Hospital Tuebingen, Tuebingen, Germany. · German Center for Infection Research (DZIF) partner site, Tuebingen, Bonn, Hannover, Heidelberg, Munich, Germany. · Department of Internal Medicine I, University of Bonn, Bonn, Germany. · Division of Gastroenterology and Hepatology, University Hospital Leipzig, Leipzig, Germany. · Department of Gastroenterology, Hepatology, and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany. · Department of Internal Medicine IV, University Hospital Heidelberg, Heidelberg, Germany. · Division of Infectious Diseases, Medizinische Poliklinik-Innenstadt, University of Munich, Munich, Germany. · Department of Hepatology and Gastroenterology, Charit√© Universit√§tsmedizin Berlin, Berlin, Germany. · Department of Gastroenterology and Hepatology, University Hospital Frankfurt, Frankfurt, Germany. · Department of Internal Medicine 3, Institute of Clinical Immunology, University Hospital Erlangen, Erlangen, Germany. · Praxis Hohenstaufenring, Cologne, Germany. · Department of Medical Oncology, Haematology, Immunology, Rheumatology and Pulmology, University Hospital Tuebingen, Tuebingen, Germany. · Department of Clinical Tumor Biology, University Hospital Tuebingen, Tuebingen, Germany. ·PLoS One · Pubmed #29874250.

ABSTRACT: OBJECTIVES: The aim of this multicenter retrospective study was to investigate safety and efficacy of direct acting antiviral (DAA) treatment in the rare subgroup of patients with HCV/HIV-coinfection and advanced liver cirrhosis on the liver transplant waiting list or after liver transplantation, respectively. METHODS: When contacting 54 German liver centers (including all 23 German liver transplant centers), 12 HCV/HIV-coinfected patients on antiretroviral combination therapy were reported having received additional DAA therapy while being on the waiting list for liver transplantation (patient characteristics: Child-Pugh A (n = 6), B (n = 5), C (n = 1); MELD range 7-21; HCC (n = 2); HCV genotype 1a (n = 8), 1b (n = 2), 4 (n = 2)). Furthermore, 2 HCV/HIV-coinfected patients were denoted having received DAA therapy after liver transplantation (characteristics: HCV genotype 1a (n = 1), 4 (n = 1)). RESULTS: Applied DAA regimens were SOF/DAC (n = 7), SOF/LDV/RBV (n = 3), SOF/RBV (n = 3), PTV/r/OBV/DSV (n = 1), or PTV/r/OBV/DSV/RBV (n = 1), respectively. All patients achieved SVR 12, in the end. In one patient, HCV relapse occurred after 24 weeks of SOF/DAC therapy; subsequent treatment with 12 weeks PTV/r/OBV/DSV achieved SVR 12. One patient underwent liver transplantation while on DAA treatment. Analysis of liver function revealed either stable parameters or even significant improvement during DAA therapy and in follow-up. MELD scores were found to improve in 9/13 therapies in patients on the waiting list for liver transplantation; in only 2 patients a moderate increase of MELD scores persisted at the end of follow-up. CONCLUSION: DAA treatment was safe and highly effective in this nation-wide cohort of patients with HCV/HIV-coinfection awaiting liver transplantation or being transplanted.